Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Gina Berardinelli

Nurse Practitioner, Adult Health Mentor, OH Nurse Practitioner

NPI 1003079922 CMS profile 10466083

9485 Mentor Ave Ste 102, Mentor, OH 44060

Open in the dashboard

General payments

$10,888

697 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gina Berardinelli of Mentor, OH is reported in the CMS Open Payments database as having received $10,888 across 697 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,387 140
2024 General $2,789 165
2023 General $2,676 173
2022 General $1,700 123
2021 General $1,335 96

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gina Berardinelli
  • Nurse Practitioner, Adult Health median
  • Middle half of Nurse Practitioner, Adult Health
  • National median

In program year 2025, general payments to Gina Berardinelli were reported at $2,387. Among 12,696 Nurse Practitioner, Adult Health profiles paid that year, the median was $184 and the middle half received between $59 and $580.

Show as a table
Year Gina Berardinelli Nurse Practitioner, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,335 $138 $43–$438 $132
2022 $1,700 $165 $54–$494 $149
2023 $2,676 $178 $61–$549 $160
2024 $2,789 $186 $62–$575 $164
2025 $2,387 $184 $59–$580 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,711 111 payments
  2. LEO Pharma Inc. $1,344 106 payments
  3. E.R. Squibb & Sons, L.L.C. $1,136 87 payments
  4. Novartis Pharmaceuticals Corporation $976 53 payments
  5. Genzyme Corporation $823 47 payments
  6. Amgen Inc. $735 49 payments
  7. UCB, Inc. $734 65 payments
  8. Lilly USA, LLC $711 41 payments
  9. Janssen Biotech, Inc. $477 24 payments
  10. Pfizer Inc. $320 24 payments
  11. Other $1,921 90 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,175 688 payments
  2. Education $713 9 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT $1,437 71 payments
  2. ADBRY $1,120 84 payments
  3. SOTYKTU $1,114 84 payments
  4. RINVOQ $940 48 payments
  5. Otezla $735 49 payments
  6. SKYRIZI $600 48 payments
  7. TALTZ $519 31 payments
  8. TREMFYA $447 22 payments
  9. Bimzelx $427 36 payments
  10. Cimzia $307 29 payments
  11. Other $3,856 251 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

1,515

Median for Nurse Practitioner: 389

Drug cost

$650,673

Median for Nurse Practitioner: $21,885

Branded share of claims

8.1%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Otezla Apremilast Brand 52 $244,664
Humira(Cf) Pen Adalimumab Brand 18 $189,337
Adbry Tralokinumab-Ldrm Brand 41 $150,920
Opzelura Ruxolitinib Phosphate Brand 11 $21,797
Clobetasol Propionate Generic 81 $5,701
Fluocinonide Generic 129 $5,192
Econazole Nitrate Generic 56 $4,202
Metronidazole Generic 85 $4,073
Doxycycline Monohydrate Generic 134 $3,724
Calcipotriene Generic 18 $3,576

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$145,341

Of which drugs: $42,295

Medicare patients

645

Average age 75

Services billed

3,924

363 women, 282 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 51%
Diabetes 25%
Ischemic heart disease 22%
Chronic kidney disease 20%
Osteoporosis 18%
Cancer 16%
Depression 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 21 65 $42

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $351
$351 — —
ADBRY
  • LEO Pharma Inc. $313
$313 41 —
DUPIXENT
  • GENZYME CORPORATION $156
  • SANOFI-AVENTIS U.S. LLC $85
  • Regeneron Healthcare Solutions, Inc. $72
$313 — —
Bimzelx
  • UCB, Inc. $221
$221 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $211
$211 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

697 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Adult Health in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record